Citation: | Xiushan CHEN, Zhipeng ZHONG, Qiaohuan LI, Ke LI. Effects of DPP4 inhibitor and long-acting insulin therapy on blood biochemical indexes of type 2 diabetes: a comparative study[J]. Journal of Molecular Imaging, 2018, 41(2): 271-273. doi: 10.3969/j.issn.1674-4500.2018.02.32 |
[1] |
Mex O. A study of peripheral arterial disease in type2 diabetes mellitus[J]. J Assoc Physicians India, 2016, 64(1): 40-4.
|
[2] |
Bashier MA. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial[J]. J Diabetes Metab Disord, 2015,14(5): 48-52.
|
[3] |
中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J]. 中国糖尿病杂志, 2014, 22(8): 42-4. http://guide.medlive.cn/guideline/5332
|
[4] |
Staiger H, Staiger K, Boehm A, et al. DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity[J]. PLoS One, 2013, 62(1): A433-4. http://paperity.org/p/80384549/dpp4-gene-variation-affects-glp-1-secretion-insulin-secretion-and-glucose-tolerance-in
|
[5] |
Xia C, Goud A, D'souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure[J]. Heart Fail Rev, 2017, 22(3): 299-304. doi: 10.1007/s10741-017-9617-4
|
[6] |
Chalichem NS, Gonugunta C, Krishnamurthy PT, et al. DPP4 inhibitors can be a drug of choice for type 3 diabetes: a mini review[J]. Am J Alzheimers Dis Other Demen, 2017, 32(7): 444-51. doi: 10.1177/1533317517722005
|
[7] |
Mousavi S. Pharmacogenetic variation of SLC47A1 gene and metformin response in type2 diabetes patients[J]. Mol Biol Res Commun, 2017, 6(2): 91-4.
|
[8] |
谢宝强. 甘精胰岛素联合瑞格列奈治疗2型糖尿病临床疗效分析[J]. 现代预防医学, 2012, 39(21): 5786-9. http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_xdyfyx201221117
|
[9] |
Bistola V. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors[J]. Heart Fail Rev ,2018,14(11):275-80. doi: 10.1007/s10741-018-9674-3
|
[10] |
Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases[J]. IUBMB Life, 2018, 70(2): 112-9. doi: 10.1002/iub.v70.2
|
[11] |
Birnbaum Y. Combined SGLT2 and DPP4 inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes[J]. Cardiovasc Drugs Ther, 2018,23(7):127-33. doi: 10.1007/s10557-018-6778-x.pdf
|
[12] |
陶桂香, 徐 洋. 1型糖尿病发病机制及治疗研究[J]. 中国免疫学杂志, 2015,28(10): 1297-303. doi: 10.3969/j.issn.1000-484X.2015.10.001
|
[13] |
陈 姬, 杨冯睿. 2型糖尿病合并视网膜病变老年患者血清脂联素及同型半胱氨酸的水平分析[J].重庆医学, 1994, 45(33): 51-2.
|
[14] |
Alipour A, Zare H, Poursharifi H, et al. The intermediary role of Self-Efficacy in relation with stress, glycosylated haemoglobin and Health-Related quality of Life in patients with type2 diabetes[J]. Iran J Public Health, 2012, 41(12): 76-80.
|
[15] |
Zhou BJ. The benefits and risks of DPP4-inhibitors vs sulfonylureas for patients with type 2 diabetes:accumulated evidence from randomised controlled trial[J].Int J Clin Pract, 2016, 70(2): 132-41. doi: 10.1111/ijcp.2016.70.issue-2
|
[16] |
张 坤, 任巧华, 吴 韬, 等. 西格列汀联合二甲双胍治疗2型糖尿病合并代谢综合征的临床观察[J]. 中国药房, 2016, 27(17): 2364-6. doi: 10.6039/j.issn.1001-0408.2016.17.20
|
[17] |
Pirdehghan A, Poortalebi N. Predictors of adherence to type2 diabetes medication[J]. J Res Health Sci, 2016, 16(2): 72-5. http://europepmc.org/abstract/MED/27497773
|